The therapeutic efficacy of Iobenguane can be decreased when used in combination with Phentermine. Caroxazone may increase the hypotensive activities of Penbutolol. The metabolism of Calcitriol can be decreased when combined with Clemastine. The metabolism of Acetylsalicylic acid can be decreased when combined with Fluorouracil. The serum concentration of Elvitegravir can be decreased when it is combined with Efavirenz. Ramipril may increase the hypotensive activities of Bimatoprost. The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cilazapril. The metabolism of Cyclophosphamide can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Droxicam. The risk or severity of adverse effects can be increased when Atenolol is combined with Etacrynic acid. The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Epetraborole. The risk or severity of adverse effects can be increased when Tenoxicam is combined with Difluocortolone. The risk or severity of adverse effects can be increased when Tirofiban is combined with Carbaspirin calcium. The serum concentration of Quinidine can be increased when it is combined with Efinaconazole. Magnesium Hydroxide may decrease the excretion rate of Chlorphentermine which could result in a higher serum level. Mefloquine may increase the QTc-prolonging activities of Gadobenic acid. The risk or severity of adverse effects can be increased when Tranilast is combined with Dexamethasone. The metabolism of Phenacetin can be decreased when combined with Chloramphenicol. Fluorometholone may increase the fluid retaining activities of Methyltestosterone. The serum concentration of Ergotamine can be increased when it is combined with Asunaprevir. The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Eplerenone. The serum concentration of Nilvadipine can be increased when it is combined with Simeprevir. The metabolism of Indacaterol can be increased when combined with Carbamazepine. The metabolism of Pyrazinamide can be decreased when combined with Ketoconazole. Enalapril may increase the hypotensive activities of Trichlormethiazide. The risk or severity of adverse effects can be increased when Reserpine is combined with Clemastine. The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Olopatadine. The serum concentration of Brexpiprazole can be increased when it is combined with Cholecalciferol. The risk or severity of adverse effects can be increased when Diclofenamide is combined with Primidone. Pargyline may increase the central nervous system depressant (CNS depressant) and hypertensive activities of Fentanyl. Prazosin may increase the hypotensive activities of Phenoxybenzamine. The metabolism of Atorvastatin can be decreased when combined with Rosiglitazone. Chlorthalidone may decrease the excretion rate of Calcium Citrate which could result in a higher serum level. Secobarbital may increase the hypotensive activities of Mecamylamine. The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Thyroid, porcine. The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Meclizine. The serum concentration of Pioglitazone can be increased when it is combined with Aprepitant. The risk or severity of adverse effects can be increased when Ibuprofen is combined with Prasterone. The serum concentration of Clomipramine can be increased when it is combined with Zofenopril. Reserpine may increase the hypotensive activities of Lercanidipine. Tolbutamide may increase the hypoglycemic activities of Mecasermin. Thiethylperazine may increase the hypotensive activities of Nadolol. The risk or severity of adverse effects can be increased when Fusidic Acid is combined with Pitavastatin. The therapeutic efficacy of Metolazone can be decreased when used in combination with Tarenflurbil. The metabolism of Sibutramine can be decreased when combined with Atazanavir. Oxycodone may increase the serotonergic activities of Etoperidone. The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Nelfinavir. The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Alclometasone. The serum concentration of Apramycin can be decreased when it is combined with Tazobactam. Minocycline may increase the central nervous system depressant (CNS depressant) activities of Butorphanol. The risk or severity of adverse effects can be increased when Ketobemidone is combined with Melperone. The risk or severity of adverse effects can be increased when Methysergide is combined with Pilocarpine. Iproclozide may increase the hypertensive activities of Phenylephrine. The metabolism of Fenofibrate can be increased when combined with Phenobarbital. The risk or severity of adverse effects can be increased when Estazolam is combined with Methaqualone. Manidipine may increase the hypotensive activities of Cicletanine. The risk or severity of adverse effects can be increased when Etanercept is combined with Phenylbutazone. The risk or severity of adverse effects can be increased when Curcumin is combined with Dexamethasone. Diclofenac may increase the anticoagulant activities of Fondaparinux. Tarenflurbil may decrease the excretion rate of Netilmicin which could result in a higher serum level. The metabolism of Dasatinib can be decreased when combined with Clemastine. Betamethasone may increase the hypokalemic activities of Chlorothiazide. The metabolism of Palonosetron can be decreased when combined with Tenofovir disoproxil. Clindamycin may increase the neuromuscular blocking activities of Doxacurium chloride. The serum concentration of Topotecan can be increased when it is combined with Dihydroergotamine. The risk or severity of adverse effects can be increased when Naproxen is combined with Prasterone sulfate. The risk or severity of adverse effects can be increased when Higenamine is combined with Prednisolone. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Ginkgo biloba. The therapeutic efficacy of Dextran 40 can be decreased when used in combination with Dydrogesterone. Procarbazine may increase the hypotensive activities of Timolol. The serum concentration of Simvastatin can be increased when it is combined with Antithrombin III human. The serum concentration of Oxtriphylline can be increased when it is combined with Peginterferon alfa-2b. The risk or severity of adverse effects can be increased when Olmesartan is combined with Nafamostat. The metabolism of Irbesartan can be decreased when combined with Teriflunomide. The risk or severity of adverse effects can be increased when Moexipril is combined with Niflumic Acid. Tolmetin may decrease the antihypertensive activities of Platelet Activating Factor. The risk or severity of adverse effects can be increased when Amphotericin B is combined with Mannitol. The metabolism of Alprenolol can be decreased when combined with Clemastine. The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Artemether. The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Desonide. Lumiracoxib may increase the thrombogenic activities of Estrone. The serum concentration of Flumethasone can be increased when it is combined with Nelfinavir. The therapeutic efficacy of Buformin can be decreased when used in combination with Diazoxide. Minocycline may increase the neuromuscular blocking activities of Cisatracurium besylate. The risk or severity of adverse effects can be increased when Dyclonine is combined with Methaqualone. The serum concentration of Fluticasone propionate can be increased when it is combined with Ethinyl Estradiol. The risk or severity of adverse effects can be increased when Dapsone is combined with Acetaminophen. The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Etidocaine. The serum concentration of Ethanol can be decreased when it is combined with St. John's Wort. The therapeutic efficacy of Beclomethasone dipropionate can be decreased when used in combination with Mifepristone. Dihydralazine may increase the hypotensive activities of Indapamide. Hydrocortisone may increase the fluid retaining activities of Danazol. Rofecoxib may increase the anticoagulant activities of Becaplermin. Clemastine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. The risk or severity of adverse effects can be increased when Tizanidine is combined with Hydralazine. Verapamil may increase the hypotensive activities of Indenolol. The therapeutic efficacy of Heparin can be decreased when used in combination with Levonorgestrel. The risk or severity of adverse effects can be increased when Carbetocin is combined with Hydralazine. The risk or severity of adverse effects can be increased when Amiodarone is combined with Perindopril. The metabolism of Icotinib can be decreased when combined with Verapamil. The metabolism of Acetaminophen can be decreased when combined with Cyclosporine. The risk or severity of adverse effects can be increased when Verapamil is combined with Methyldopa. The risk or severity of adverse effects can be increased when Amlodipine is combined with Isosorbide Mononitrate. Salbutamol may increase the QTc-prolonging activities of Quinine. The risk or severity of adverse effects can be increased when Hexobarbital is combined with Brompheniramine. The risk or severity of adverse effects can be increased when Cinnarizine is combined with Magnesium oxide. 2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Opium. The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Aripiprazole. Chlorothiazide may increase the hypotensive activities of Epoprostenol. The serum concentration of Amodiaquine can be increased when it is combined with Gemfibrozil. Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine. Sodium bicarbonate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. The metabolism of Vilanterol can be decreased when combined with Nefazodone. Cholestyramine can cause a decrease in the absorption of Hydrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy. The metabolism of Icotinib can be decreased when combined with Darunavir. Aliskiren may increase the hyperkalemic activities of Enalaprilat. The risk or severity of adverse effects can be increased when Quinapril is combined with Ibuproxam. Amobarbital may increase the hypotensive activities of Nifedipine. Minocycline may increase the central nervous system depressant (CNS depressant) activities of Zopiclone. The risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorothiazide. Clonidine may increase the hypotensive activities of Amifostine. Brofaromine may increase the hypotensive activities of Deserpidine. The risk or severity of adverse effects can be increased when Ethyl chloride is combined with Clonidine. The serum concentration of Ipratropium bromide can be increased when it is combined with Netupitant. The risk or severity of adverse effects can be increased when Dyclonine is combined with Raclopride. The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ketotifen. Ramipril may increase the hypotensive activities of Hydroflumethiazide. The metabolism of Synthetic Conjugated Estrogens, B can be increased when combined with Pentobarbital. Tadalafil may increase the antihypertensive activities of Dihydralazine. Polymyxin B Sulfate may increase the neuromuscular blocking activities of Cisatracurium besylate.